Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared to historical controls (n=157). Patients (n=55...

Descripción completa

Detalles Bibliográficos
Autores principales: Shadman, Mazyar, Maloney, David G., Storer, Barry, Sandmaier, Brenda M., Chauncey, Thomas R., Andersen, Niels Smedegaard, Niederwieser, Dietger, Shizuru, Judith, Bruno, Benedetto, Pulsipher, Michael A., Maziarz, Richard T., Agura, Edward D., Hari, Parameswaran, Langston, Amelia A., Maris, Michael B., McSweeney, Peter A, Storb, Rainer, Sorror, Mohamed L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940535/
https://www.ncbi.nlm.nih.gov/pubmed/31481800
http://dx.doi.org/10.1038/s41409-019-0660-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940535/
https://www.ncbi.nlm.nih.gov/pubmed/31481800
http://dx.doi.org/10.1038/s41409-019-0660-8

Ejemplares similares